The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Evidence of Clozapine’s Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials
Abstract
OBJECTIVE: The purpose of this study was to evaluate all available trial-based evidence on the effectiveness of clozapine in schizophrenia as compared with conventional neuroleptics. METHOD: All randomized, controlled trials comparing clozapine with a conventional neuroleptic in which there was satisfactory concealment of patients' treatment allocation were located through electronic searches in all languages of several databases and through contacting authors of recent trials as well as the manufacturer of clozapine. At least two independent reviewers assessed trials for inclusion in the study and extracted data for meta-analysis. RESULTS: The review included 2,530 randomly assigned participants in 30 trials, most of them short-term. Clozapine-treated patients showed more clinical improvement and experienced significantly fewer relapses during treatment, although the risk of blood dyscrasias in long-term treatment may be as high as 7%. Scores on symptom rating scales showed greater improvement among clozapine-treated patients, who were also more satisfied with their treatment. However, there was no evidence that the superior clinical effect of clozapine is reflected in levels of functioning; on the other hand, global functional and pragmatic outcomes were frequently not reported. Clinical improvement was most pronounced in patients with treatment-resistant illness. CONCLUSIONS: This meta-analysis confirms that clozapine is more effective than conventional neuroleptics in reducing symptoms of patients with both treatment-resistant and nonresistant schizophrenia. Future trials should be long-term pragmatic community trials or should address the effectiveness of clozapine in special patient populations. An international standard set of outcomes, including pragmatic assessments of functioning, would greatly enhance the comparison and summation of trials and future assessments of effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109
Systematic Reviews: Rationale for systematic reviews
Mulrow, C. D. (1994) · BMJ · doi:10.1136/bmj.309.6954.597 · Cited by 1,677
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
Meta-Analyses of Randomized Controlled Trials
Sacks, H. S., Berrier, J., Reitman, D., Ancona-Berk, V. A., & Chalmers, T. C. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702193160806 · Cited by 1,250
Language bias in randomised controlled trials published in English and German
Egger, M., Zellweger-Zähner, T., Schneider, M., Junker, C., Lengeler, C., & Antes, G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02419-7 · Cited by 1,028
Research works printed but not linked: 25
- Angst J, Jaenicke U, Padrutt A, Scharfetter C: Ergebnisse eines doppelblindversuches von HF 1854 (8-Chlor-11-(4 methyl-1-piperazinyl)-5H-dibeno (b,e) (1,4) diazepine) im Vergleich zu Levomepromazin. Pharmakopsychiatrie, Neuro-Psychopharmakologie 1971; 4:192–200 · doi:10.1055/s-0028-1094312
- van Praag HM, Korf J, Dols LC: Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. Br J Psychiatry 1976; 129:547–555 · doi:10.1192/bjp.129.6.547
- Bao XG: [A double-blind study on the effect of clozapine, penfluridol, and chlorpromazine in the treatment of schizophrenia] (Chinese). Chung Hua Shen Ching Ching Shen Ko Tsa Chih 1988; 21:274–276
- Ruiz Ruiz M: Estudio doble ciego comparativo entre clozapina y clorpromacina en las esquizofrenias. Arch Neurobiol (Madrid) 1974; 37:169–180
- Yang WJ: [Three antipsychotic drugs in the treatment of schizophrenia—a controlled and double-blind study] (Chinese). Chung Hua Shen Ching Ching Shen Ko Tsa Chih 1988; 21:277–280, 318–319
- Li Y: [Application of NOSIE in the study of neuroleptic treatment] (Chinese). Chung Hua Shen Ching Ching Shen Ko Tsa Chih 1987; 20:325–327
- Nahunek K, Svestka J, Misurec J, Rodova A: Klinické zkusenosti s clozpinem [Clinical experience with clozapine]. Cesk Psychiatr 1975; 71:11–16
- Leon CA, Estrada H: Efectos terapeuticos de la clozapina sobre los sintomas de psicosis. Revista Colombiana de Psiquiatria 1974; 3:309–318
- Fischer-Cornelssen K, Ferner U, Steiner H: Multifokale Psychopharmakaprüfung. Arzneimittelforschung 1974; 24:1006–1007
- Fischer-Cornelssen K, Ferner U, Steiner H: Multifokale Psychopharmakaprüfung (“Multihospital Trial”). Arzneimittelforschung 1974; 24:1706–1724
- Dick P, Rémy M, Rey-Bellet JJ: Essai de comparaison de deux antipsychotiques: la chlorpromazine et la clozapine [Comparison of two antipsychotic drugs: chlorpromazine and clozapine]. Ther Umsch 1975; 32:497–500
- Vencovsky E, Peterova E, Baudis P: Srovnáni terapeutického úcinku clozapinu s chlorpromazinem [Comparison of the therapeutic effect of clozapine and chlorpromazine]. Cesk Psychiatr 1975; 71:21–26
- Honigfeld G, Patin J, Singer J: Clozapine antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy 1984; 1:77–97
- Singer K, Law S: Comparative double-blind study with clozapine (Leponex) and chlorpromazine in acute schizophrenia. J Int Med Res 1974; 2:433–435
- Chiu E, Burrows G, Stevenson J: Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness. Aust NZ J Psychiatry 1976; 10:343–347 · doi:10.3109/00048677609159524
- Ciurezu T, Ionescu R, Nica-Udangiu S, Niturad D, Oproiu L, Tudorache D, Popovici I, Curelaru S: Étude clinique en “double blind” du HF 1854 (=LX 100-129=clozapine=Leponex) comparé à l´halopéridol. Neurol Psychiatr (Bucur) 1976; 14:29–34
- Guirguis E, Voineskos G, Gray J, Schlieman E: Clozapine (Leponex) vs chlorpromazine (Largactil) in acute schizophrenia (a double-blind controlled study). Curr Ther Res 1977; 21:707–719
- Itoh H, Miura S, Yagi G, Sakurai S, Ohtsuka N: Some methodological considerations for the clinical evaluation of neuroleptics—comparative effects of clozapine and haloperidol on schizophrenics. Folia Psychiatr Neurol Jpn 1977; 31:17–24 · doi:10.1111/j.1440-1819.1977.tb02679.x
- Erlandsen C: Utprøving av et nytt nevroleptikum, Leponex (clozapin) hos schizofrene med lang sykehistorie. Nordic J Psychiatry 1981; 35:248–253 · doi:10.3109/08039488109100827
- Shopsin B, Klein H, Aaronsom M, Collora M: Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 1979; 36:657–664 · doi:10.1001/archpsyc.1979.01780060047005
- Klein H, Aronson M, Shopsin B: Clozapine: double-blind controlled trial in the treatment of schizophrenia. Psychopharmacol Bull 1978; 14:12–15
- Xu WR, Bao-long Z, Qui C, Mei-fang G: A double-blind study of clozapine and chlorpromazine treatment in the schizophrenics. Chinese J Nervous and Ment Disease 1985; 11:222–224
- Liu BL, Chen YY, Yang DS: [Effects of thioridazine on schizophrenics and clinical utility of plasma levels] (Chinese). Chin J Neurol Psychiatry 1994; 27:364–367
- Marder SR, Kane JM, Schooler NR, Wirshing WC, Baker R, Ames D, Umbricht D, Ganguli R, Borenstein M: Effectiveness of clozapine in treatment resistant schizophrenia (abstract). Schizophr Res 1997; 24:187 · doi:10.1016/s0920-9964(97)82533-9
- Wirshing WC, Baker R, Umbricht D, Ames D, Schooler N, Kane J, Marder SR, Borenstein D: Clozapine vs haloperidol: drug intolerance in a controlled six month trial (abstract). Schizophr Res 1997; 24:268 · doi:10.1016/s0920-9964(97)82772-7
Cited by
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Mueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 601
Metadata
- Authors
- Wahlbeck, K., Cheine, M., Essali, A., & Adams, C.
- Venue
- American Journal of Psychiatry
- Published
- 1999-07-01
- Volume
- 156
- Issue
- 7
- Pages
- 990-999
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1963015295
- Cited by
- 357
- References
- 34
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence of Clozapine’s Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials. https://app.cochat.ai/papers/10.1176/ajp.156.7.990
- The paper
- Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999). Evidence of Clozapine’s Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials. American Journal of Psychiatry. https://doi.org/10.1176/ajp.156.7.990
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.